Kimberly-Clark
KMB
96.48
-0.29
-0.30%
Kimberly-Clark
US · KMB
#638 by market cap
Listed 1970
96.48
-0.29
-0.30%
Live - 5344 symbols - heartbeat 116s ago
· 2026-10-08 06:22
Pre-market
96.80
+0.33%
After-hours
97.33
+0.88%
Overnight
96.48
0.00%
- Market cap
- 32.09B
- P/E (TTM)i
- 16.44
- P/Bi
- 18.34
- EPSi
- 6.07
- Div yieldi
- 5.27%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on KMB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.32, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.13% YoY
Margins
- Gross margin
- 36.01%
- Operating margin
- 14.29%
- Net margin
- 12.29%
Key ratios & quality
- Enterprise valuei
- 38.61B
- PEG ratioi
- 11.12
- Altman Z-Scorei
- 3.32
PEG uses trailing P/E against the 3-year net income growth rate (1.48%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.49B | 18.45B | 19.14B | 19.44B | 20.18B | 17.15B | 16.81B | 16.45B |
| Gross profit | 5.60B | 6.04B | 6.82B | 5.99B | 6.22B | 6.27B | 6.29B | 5.92B |
| Selling & admin expenses | 3.37B | 3.25B | 3.63B | 3.40B | 3.58B | 3.62B | 3.93B | 3.53B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.23B | 2.99B | 3.24B | 2.56B | 2.68B | 2.59B | 2.80B | 2.35B |
| Pretax profit | 1.81B | 2.65B | 2.93B | 2.23B | 2.34B | 1.61B | 2.42B | 2.05B |
| Tax | 471.00M | 576.00M | 676.00M | 479.00M | 495.00M | 343.00M | 442.00M | 599.00M |
| Net profit | 1.45B | 2.20B | 2.40B | 1.84B | 1.96B | 1.76B | 2.58B | 2.05B |
| Basic EPS | 4 | 6 | 7 | 5 | 6 | 5 | 8 | 6 |
| Diluted EPS | 4.03 | 6.24 | 6.87 | 5.35 | 5.72 | 5.21 | 7.55 | 6.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.05B | 4.16B | 4.15B | 4.08B | 4.16B | 4.19B |
| Gross profit | 1.51B | 1.46B | 1.49B | 1.47B | 1.53B | 1.60B |
| Selling & admin expenses | 855.00M | 863.00M | 855.00M | 955.00M | 920.00M | 1.00B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 631.00M | 592.00M | 621.00M | 507.00M | 753.00M | 633.00M |
| Pretax profit | 557.00M | 513.00M | 546.00M | 436.00M | 685.00M | 572.00M |
| Tax | 131.00M | 116.00M | 248.00M | 104.00M | 164.00M | 217.00M |
| Net profit | 573.00M | 512.00M | 454.00M | 510.00M | 675.00M | 350.00M |
| Basic EPS | 2 | 2 | 1 | 2 | 2 | 1 |
| Diluted EPS | 1.70 | 1.53 | 1.34 | 1.50 | 2.00 | 1.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 5.04B | 5.06B | 5.17B | 5.57B | 5.73B | 5.70B | 5.58B | 5.31B |
| Cash & ST investments | 539.00M | 442.00M | 303.00M | 270.00M | 427.00M | 1.09B | 1.18B | 774.00M |
| Inventory | 1.81B | 1.79B | 1.90B | 2.24B | 2.27B | 1.96B | 1.45B | 1.48B |
| Total assets | 14.52B | 15.28B | 17.52B | 17.84B | 17.97B | 17.34B | 16.55B | 17.10B |
| Total current liabilities | 6.54B | 6.92B | 6.44B | 6.75B | 7.33B | 6.93B | 7.00B | 7.13B |
| Short-term debt | 1.21B | 1.66B | 619.00M | 563.00M | 971.00M | 697.00M | 680.00M | 822.00M |
| Long-term debt | 6.25B | 6.21B | 7.88B | 8.14B | 7.58B | 7.42B | 6.85B | 6.47B |
| Total liabilities | 14,564,000,000.00 | 15,089,000,000.00 | 16,654,000,000.00 | 17,100,000,000.00 | 17,270,000,000.00 | 16,276,000,000.00 | 15,571,000,000.00 | 15,468,000,000.00 |
| Total equity | -46.00M | 194.00M | 869.00M | 737.00M | 700.00M | 1.07B | 975.00M | 1.63B |
| Retained earnings | 5.95B | 6.69B | 7.57B | 7.86B | 8.20B | 8.37B | 9.26B | 9.61B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.28B | 5.56B | 5.47B | 5.31B | 5.29B | 6.35B |
| Cash & ST investments | 563.00M | 634.00M | 617.00M | 774.00M | 542.00M | 956.00M |
| Inventory | 1.91B | 1.56B | 1.54B | 1.48B | 1.48B | 1.54B |
| Total assets | 16.31B | 16.77B | 16.89B | 17.10B | 17.18B | 18.55B |
| Total current liabilities | 6.92B | 7.17B | 7.08B | 7.13B | 6.90B | 6.99B |
| Short-term debt | 766.00M | 771.00M | 834.00M | 822.00M | 609.00M | 43.00M |
| Long-term debt | 6.48B | 6.47B | 6.47B | 6.47B | 6.48B | 6.47B |
| Total liabilities | 15,081,000,000.00 | 15,368,000,000.00 | 15,420,000,000.00 | 15,468,000,000.00 | 15,270,000,000.00 | 16,680,000,000.00 |
| Total equity | 1.22B | 1.40B | 1.47B | 1.63B | 1.91B | 1.87B |
| Retained earnings | 9.41B | 9.49B | 9.52B | 9.61B | 9.85B | 9.77B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.97B | 2.74B | 3.73B | 2.73B | 2.73B | 3.54B | 3.23B | 2.78B |
| Depreciation & amortization | 882.00M | 917.00M | 796.00M | 766.00M | 754.00M | 753.00M | 781.00M | 805.00M |
| Free cash flow | 2.09B | 1.53B | 2.51B | 1.72B | 1.86B | 2.78B | 2.51B | 1.64B |
| Dividends paid | -1.39B | -1.41B | -1.45B | -1.52B | -1.56B | -1.59B | -1.63B | -1.66B |
| Stock buybacks / issuance | -800.00M | -800.00M | -700.00M | -400.00M | -100.00M | -320.00M | -1.00B | -141.00M |
| Ending cash balance | 539.00M | 442.00M | 303.00M | 270.00M | 427.00M | 1.09B | 1.02B | 701.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 327.00M | 770.00M | 708.00M | 972.00M | 745.00M | 908.00M |
| Depreciation & amortization | 218.00M | 222.00M | 176.00M | 189.00M | 193.00M | 167.00M |
| Free cash flow | 123.00M | 573.00M | 368.00M | 575.00M | 321.00M | 556.00M |
| Dividends paid | -405.00M | -419.00M | -418.00M | -418.00M | -418.00M | -425.00M |
| Stock buybacks / issuance | -61.00M | -59.00M | -20.00M | -1.00M | 0 | 0 |
| Ending cash balance | 563.00M | 657.00M | 634.00M | 701.00M | 559.00M | 1.36B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 824.56 | -- | 793.25 | 318.25 | 364.56 | 241.31 | 290.03 | 172.59 |
| ROA %i | 9.50 | 14.48 | 14.34 | 10.26 | 10.80 | 9.99 | 15.02 | 12.01 |
| ROIC %i | 21.15 | -- | 29.94 | 21.92 | 23.43 | 21.41 | 31.23 | 25.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | 401.48 | 277.35 |
| EBIT margin %i | 11.23 | 15.78 | 16.62 | 12.76 | 13.00 | 11.33 | 15.94 | 14.03 |
| FCF / sales %i | 11.32 | 8.28 | 13.12 | 8.86 | 9.20 | 13.59 | 12.53 | 9.97 |
| Current ratioi | 0.77 | 0.73 | 0.80 | 0.82 | 0.78 | 0.82 | 0.80 | 0.75 |
| Quick ratioi | 0.41 | 0.39 | 0.39 | 0.37 | 0.37 | 0.47 | 0.43 | 0.37 |
| Debt / assetsi | 51.35 | 51.54 | 48.49 | 48.80 | 47.57 | 46.78 | 45.78 | 42.67 |
| LT debt / equityi | -- | -- | 1,258.47 | 1,583.85 | 1,385.37 | 810.60 | 818.45 | 431.03 |
| Interest coveragei | 7.89 | 11.15 | 12.63 | 9.69 | 9.30 | 7.90 | 11.84 | 9.02 |
| Revenue CAGR (3Y) %i | -0.19 | 0.30 | 1.42 | 1.69 | 3.02 | -3.60 | -4.74 | -6.58 |
| Net income CAGR (3Y) %i | 11.65 | -0.14 | 1.07 | 8.76 | -3.57 | -9.14 | 11.95 | 1.48 |
| FCF CAGR (3Y) %i | 18.75 | -14.71 | 5.42 | -6.28 | 6.74 | 3.39 | 13.41 | -4.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 229.84 | 201.91 | 150.48 | 172.59 | 146.29 | 129.43 |
| ROA %i | 14.76 | 14.27 | 11.56 | 12.01 | 12.65 | 11.07 |
| ROIC %i | 30.46 | 29.58 | 24.61 | 25.39 | 26.48 | 25.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.73 | 16.00 | 13.88 | 14.03 | 14.68 | 14.93 |
| FCF / sales %i | 12.11 | 10.66 | 8.48 | 9.97 | 11.10 | 10.98 |
| Current ratioi | 0.76 | 0.77 | 0.77 | 0.75 | 0.77 | 0.91 |
| Quick ratioi | 0.40 | 0.37 | 0.37 | 0.37 | 0.37 | 0.40 |
| Debt / assetsi | 44.45 | 43.18 | 43.25 | 42.67 | 41.22 | 35.12 |
| LT debt / equityi | 588.65 | 509.05 | 485.74 | 431.03 | 360.52 | 369.94 |
| Interest coveragei | 11.64 | 12.04 | 10.53 | 9.02 | 9.72 | 10.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Baby and Child Care is the largest reported line at 41.82% of revenue, across 6 reported segments.
- No single line clears half of revenue; Family Care is next at 24.23%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Baby and Child Care41.82%
Family Care24.23%
Adult Care11.77%
Professional11.36%
Feminine Care10.10%
All other0.72%
Quote time 2026-10-08 06:22:55 · For reference only, not investment advice and not tailored to your situation.